 |
|
Sentinel Node Biopsy for Melanoma: What Is the Evidence?
James Connors, MD;
Bruce Smoller, MD;
Scott Dinehart, MD
Arch Dermatol. 2001;137:1228-1231.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Examination of Regional Lymph Nodes by Sentinel Node Biopsy and Molecular Analysis Provides New Staging Facilities in Primary Cutaneous Melanoma
Blaheta H-J, Ellwanger U, Schittek B, Sotlar K, Maczey E, Breuninger H, Thelen MH, Bueltmann B, Rassner G, Garbe C
J Invest Dermatol. 2000;114:637-642
Blaheta et al conducted a prospective cohort study on 116 patients with newly diagnosed primary cutaneous melanoma greater than or equal to 0.9 mm in Breslow depth. No patients showed evidence of metastatic disease and all underwent sentinel lymph node (SLN) biopsy.
The objective of the study was to assess the utility of using molecular analysis for detection of submicroscopic melanoma cells in SLNs to improve the accuracy of tumor staging. Patients were followed up for a mean of 19 months (range, 2-35 months).
All 116 patients received preoperative lymphoscintigraphy to evaluate the pathways of lymphatic drainage . . . [Full Text of this Article] Editors' Comment
Little Rock, Ark
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States
Bilimoria et al.
JCO 2009;27:1857-1863.
ABSTRACT
| FULL TEXT
Melanoma Margins: The Importance and Need for More Evidence-Based Trials
Johnson and Sondak
Arch Dermatol 2004;140:1148-1150.
FULL TEXT
Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Kanzler
Arch Dermatol 2004;140:237-238.
FULL TEXT
Sentinel Lymph Node Biopsy and Adjuvant Therapy for Melanoma: Evidence Revisited
McMasters et al.
Arch Dermatol 2003;139:99-99.
FULL TEXT
|
